New eye drug could offer better vision protection for wet AMD patients
NCT ID NCT07520318
First seen Apr 16, 2026 · Last updated May 17, 2026 · Updated 5 times
Summary
This study tests a new investigational drug called OCUL101 for people with wet age-related macular degeneration (AMD), a condition that causes vision loss. The drug works by blocking two proteins that damage the eye. About 255 adults aged 50-89 who have not been treated before will receive either OCUL101 or the standard drug Eylea. The goal is to see if OCUL101 is safe and works better at preserving vision.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.